274. Osteogenesis Imperfecta Clinical trials / Disease details

Clinical trials : 87 / Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-003228-22-NL (EUCTR)	13/01/2021	27/11/2020	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Bonefos Product Name: Bonefos	University of Edinburgh	NHS Lothian	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 4	Ireland;Netherlands;United Kingdom
2	JPRN-UMIN000031290	2018/05/30	01/04/2018	Efficacy of pamidronate for adult osteogenesis imperfecta: uncontrolled study.	Efficacy of pamidronate for adult osteogenesis imperfecta: uncontrolled study. - Efficacy of pamidronate for adult osteogenesis imperfecta	Osteogenesis imperfecta	Pamidronate disodium intervenous for drip use; 15mg/day (available up to 30mg/day), 1 infection/day x 3 dats, every 4 months, total 16 months.	Kobe University Hospital	NULL	Recruiting	20years-old	Not applicable	Male and Female	10	Not applicable	Japan
3	EUCTR2016-003228-22-IE (EUCTR)	22/06/2017	03/11/2016	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Clasteon Product Name: Clasteon Trade Name: Calcichew D3 Product Name: Calcichew D3 Trade Name: Fultium-D3 800IU capsules Product Name: Fultium-D3 800IU capsules Trade Name: Prolia Product Name: Prolia	University of Edinburgh	NHS Lothian	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 4	Ireland;Netherlands;United Kingdom
4	EUCTR2016-003228-22-GB (EUCTR)	14/12/2016	19/10/2016	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Bonefos Product Name: Bonefos	University of Edinburgh	NHS Lothian	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 4	Ireland;United Kingdom
5	NCT00655681 (ClinicalTrials.gov)	September 2007	4/4/2008	Prevention of Post Operative Bone Loss in Children	Prevention of Post Operative Bone Loss in Children	Osteoporosis;Cerebral Palsy;Spina Bifida;Osteopenia;Osteogenesis Imperfecta	Drug: pamidronate;Other: saline	University of New Mexico	Thrasher Research Fund	Completed	4 Years	18 Years	Both	24	N/A	United States
6	NCT00005901 (ClinicalTrials.gov)	June 2000	6/6/2000	Pamidronate to Treat Osteogenesis Imperfecta in Children	A Trial of Pamidronate in Children With Osteogenesis Imperfecta	Osteogenesis Imperfecta	Drug: Pamidronate (Aredia)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	National Institutes of Health Clinical Center (CC)	Completed	N/A	16 Years	All	34	Phase 3	United States;Canada
7	NCT00159419 (ClinicalTrials.gov)	August 1999	7/9/2005	Bisphosphonate Therapy for Osteogenesis Imperfecta	Bisphosphonate Therapy for Osteogenesis Imperfecta	Osteogenesis Imperfecta;Osteoporosis;Paget Disease of Bone	Drug: Alendronate;Drug: Pamidronate	Indiana University School of Medicine	NULL	Completed	3 Years	21 Years	All	18	Phase 4	United States
8	EUCTR2015-003539-37-Outside-EU/EEA (EUCTR)		07/03/2016	Bisphosphonate Treatment of Osteogenesis Imperfecta	An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfect.	Osteogenesis Imperfecta;Therapeutic area: Diseases [C] - Cancer [C04]	Trade Name: Zometa	Novartis	NULL	NA			Female: yes Male: yes	158		United States